Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Zosano Pharma Corporation ZSANQ

Zosano Pharma Corp is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Zosano Pharma Corp is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Zosano Pharma Corp. Zosano Pharma Corp is a clinical-stage specialty pharmaceutical company. It has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of various indications. The company only operating segment being developing human pharmaceutical products. All the business activities of the firm is functioned through the market of the United States. Its product includes Qtrypta (M207) which is a formulation of zolmitriptan delivered utilizing an Adhesive Dermally-Applied Microarray technology.


EXPM:ZSANQ - Post by User

Post by Humaniston Jan 05, 2021 8:29am
140 Views
Post# 32222338

ZSAN TO PRESENT AT H.C. WAINWRIGHT VIRTUAL BIOCONNECT CONF.

ZSAN TO PRESENT AT H.C. WAINWRIGHT VIRTUAL BIOCONNECT CONF.Zosano Pharma to Present at the H.C. Wainwright Virtual BioConnect Conference

January 04, 2021 08:30 ET | Source: Zosano Pharma Corporation
FREMONT, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Virtual BioConnect Conference that will be available on Monday, January 11, 2021 at 6:00 am ET.

A webcast of the presentation can be accessed on the company’s website at https://ir.zosanopharma.com/events-presentations. The archived webcast will remain available for 90 days following the date of the event.


Zosano Contact:
Christine Matthews
Chief Financial Officer
510-745-1200

PR Contacts:
Sylvia Wheeler or Alexandra Santos
swheeler@wheelhouselsa.com or asantos@wheelhouselsa.com

 

<< Previous
Bullboard Posts
Next >>